TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05795413

Intervention type: PROCEDURE
Intervention: Mastectomy with PECS blocks
Description: Approximately half of patients recruited will receive a PECS block with Liposomal bupivacaine and half will not receive a block.

Intervention type: DRUG
Intervention: Liposomal bupivacaine
Description: All of the PECS blocks performed at this institution have liposomal lupivacaine as the anesthetic. Investigators will examine quality of recovery and pain control in patients who receive a PECS block versus those who do not receive one.
Study: NCT05775055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Composition of oral rehydration solutions
Description: Investigate the efficacy of an amino acid-based oral rehydration solution compared to two current commercially available glucose-based oral rehydration solutions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Composition of oral rehydration solutions
Description: Investigate the efficacy of an amino acid-based oral rehydration solution compared to two current commercially available glucose-based oral rehydration solutions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Composition of oral rehydration solutions
Description: Investigate the efficacy of an amino acid-based oral rehydration solution compared to two current commercially available glucose-based oral rehydration solutions.
Study: NCT05682092

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WonderLab Collagen Tripeptide Drink
Description: the participant in this arm will use the assigned product 25ml one time, twice a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary Drink
Description: the participant in this arm will use the assigned product 25ml one time, twice a day.
Study: NCT05838261

Intervention type: PROCEDURE
Intervention: Pharyngeal flap
Description: Children with combined or isolated cleft palate with velopharyngeal insufficiency undergoing surgical treatment with pharyngeal flap will be evaluated with patient- and parent reported outcome measures before and after the surgery.
Study: NCT06098170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unguided use of the My SCI Toolkit program
Description: Participants will be asked to use the My SCI Toolkit program for 8 weeks (without a coach), following the prompts and guides built into the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coached My SCI Toolkit
Description: Participants will be asked to use the My SCI Toolkit program for 8 weeks, following the prompts and guides built into the program. Participants will also have weekly phone calls (the first is about 30-45 minutes, and the rest are about 15 minutes) with a study coach. The coach can help answer questions and tailor the skills more to the participant's goals and needs. The coaching sessions will be audio recording for fidelity purposes.
Study: NCT05592054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon guide catheters (BGCs)
Description: MT procedure with Balloon guide catheters (BGCs)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard guide catheter
Description: MT procedure with standard guide catheter
Study: NCT06206967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion
Description: This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about thromboembolism pathophysiology and its management, healthy-lifestyle habits, benefits of early-mobilisation, and any questions patients may have would be answered.~Additionally, an early-mobilization program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
Study: NCT06484036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment strategy
Description: Periodontal treatment sessions (Experimental Group only) (1 to 3 months) after randomization
Study: NCT05189626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: Post Isometric relaxation(muscle energy technique) 3 days/ week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaltonborn mobilizations
Description: Kaltonborn mobilizations grade II and III will be performed on Glenohumeral joints 3 days/ week for 4 weeks.
Study: NCT05584852

Intervention type: OTHER
Description: no intervention

Intervention type: OTHER
Description: no intervention
Study: NCT06070402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAL, a voice-controlled virtual assistant
Description: Participants in the experimental group will test in their homes a device called DIAL, a voice-controlled virtual assistant designed to communicate with the elderly and help them in different contexts. They will use it for four weeks. They will receive an individual training session on how to use the device, an instruction sheet for its use and, in addition, they will receive telephone technical support throughout the study. Finally, the device will be uninstalled and all participants will be called back to answer the same survey they answered before the intervention.
Study: NCT05168579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deliberate practice
Description: As above
Study: NCT05172817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advixa (Adalimumab)
Description: Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advixa (Adalimumab)
Description: Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.
Study: NCT05797922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 0.3mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 0.3mg
Study: NCT06550336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25.Each 4-week period constitutes one treatment cycle.
Study: NCT05570006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-668
Description: Oral Capsule
Study: NCT06492980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: triple-branched stent graft
Description: a triple-branched stent graft for aortic arch repairement during surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: triple-branched stent graft
Description: a triple-branched stent graft for aortic arch repairement during surgery
Study: NCT05808738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic play
Description: therapeutic game will be played to prepare children for hydrotherapy treatment
Study: NCT06170775

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulp therapy
Description: Pulp capping material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulp therapy
Description: Pulp capping material

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodiumhexametaphosphate
Description: Sodiumhexametaphosphate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: MTA
Study: NCT05009524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPACES (interactive Physical and Cognitive Exercise System)
Description: iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PACE (Physical and Cognitive Exercise)
Description: PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations.
Study: NCT05399485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
Study: NCT05701917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClotTriever System
Description: Mechanical thrombectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Description: Anticoagulants are a group of medications that decrease your blood's ability to clot.
Study: NCT05324969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MM-based MI
Description: 9 remote mindful-based MI sessions will be delivered to promote participating parents' mindful eating, mindful movements, and mindful family interactions. Parents will be encouraged to act as changing agents for their families.

Intervention type: OTHER
Group type: OTHER
Intervention: healthy education
Description: 9 health education emails will be sent to participating parents in the control group
Study: NCT05743231

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interpectoral area block + serratus anterior area block group
Description: The interpectoral and serratus anterior area blocks will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used for two blocks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interpectoral area block + serratus anterior area block group
Description: The interpectoral and serratus anterior area blocks will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used for two blocks.
Study: NCT01487278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misprostol
Description: 600 mcg misoprostol oral

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UnijectTM
Description: 10 IU oxytocin delivered intramuscularly with UnijectTM
Study: NCT05001438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hidro
Description: Guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hidro
Description: Guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MUA
Description: Movilization under anesthesia
Study: NCT04932499

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants randomly assigned to this intervention will receive standard of care given to all patients undergoing total knee arthroplasty at our institution as outlined in the Common Care Pathway for Total Joint Replacement. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants randomly assigned to this intervention will receive standard of care given to all patients undergoing total knee arthroplasty at our institution as outlined in the Common Care Pathway for Total Joint Replacement. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: In addition to standard of care, participants randomly assigned to the treatment group will be given a 45-60 minute teaching session on mindfulness meditation. Upon completion of this session, participants will be given homework recordings of a body scan exercise and asked to listen to the recording daily for the two-week period prior to surgery. Participants will be asked to listen to their recording immediately prior to their surgery and daily while in hospital. In addition, participants assigned to mindfulness intervention will receive standard of care as outlined in the control group. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative.
Study: NCT05753683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth-Women's CoOp
Description: The mHealth-Women's CoOp, was developed and tested in a previous randomized trial, is a gender-specific human immunodeficiency virus (HIV) risk-reduction intervention that addresses the intersection of substance use, sexual risk and gender-based violence through education, skills-building, and role-play and rehearsal via a mobile app. The mHealth-Women's CoOp app is also used to help participants monitor progress toward their goals throughout the study period. Specifically, the app is programmed to prompt the user, to visit the app and participate in several activities, including health and behavior check-in and revisiting aspects of the mHealth-Women's CoOp educational content to sustain risk reduction.
Study: NCT04850638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 tablets and furosemide tablets
Description: SHR4640 tablets and furosemide tablets
Study: NCT05753683

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth-Women's CoOp
Description: The mHealth-Women's CoOp, was developed and tested in a previous randomized trial, is a gender-specific human immunodeficiency virus (HIV) risk-reduction intervention that addresses the intersection of substance use, sexual risk and gender-based violence through education, skills-building, and role-play and rehearsal via a mobile app. The mHealth-Women's CoOp app is also used to help participants monitor progress toward their goals throughout the study period. Specifically, the app is programmed to prompt the user, to visit the app and participate in several activities, including health and behavior check-in and revisiting aspects of the mHealth-Women's CoOp educational content to sustain risk reduction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Group
Description: The enhanced online group component will be available to be accessed using the mHealth-Women's CoOp platform for participants in the enhanced arm. The purpose of this component is to allow for young women who use alcohol to interact with young women like them and also discuss issues related to substance use and sexual risk-taking via a guided conversation to allow for motivational and informational support. The virtual group component will include online live discussions moderated and monitored by a trained online facilitator.
Study: NCT05250310

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chair Yoga
Description: Yoga poses performed in a chair
Study: NCT04757987

Intervention type: OTHER
Intervention: Pain
Description: As above
Study: NCT06103825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Description: solriamfetol : QD，PO，Day 1-Day 84；
Study: NCT04074681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Internet-based Protocol
Description: Gambling Internet-based protocol is a multimedia interactive and self-help program for problem and pathological gamblers, which will allow individuals to learn and practice adaptive ways to cope with this problem. The main therapeutic modules included in this program are: 1) Motivational for change; 2) Psychoeducation; 3) Stimulus control (e.g. self-prohibition and blocking of usual gambling websites with therapist confirmation) and responsible return of debts; 4) Cognitive restructuring; 5) Emotion regulation; 6) Planning of significant activities; 7) Coping skills and exposure with response prevention; 8) Relapse prevention.
Study: NCT05532852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard-of-care plus Paxlovid
Description: standard-of-care plus Paxlovid

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: standard-of-care
Description: standard-of-care
Study: NCT06103825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo :QD，PO，Day 1-Day 84
Study: NCT05904470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir
Description: 550 mg administered orally once a day (QD) for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: 180 mg administered orally once a day (QD) for 8 weeks
Study: NCT05033223

Intervention type: OTHER
Group type: OTHER
Intervention: PTSD evaluation of emergency room staff 9 and 12 months after the end of second lockdown in France during COvid-19 pandemic
Description: PCL-5 autoquestionnaire to make the PTSD diagnosis
Study: NCT04665505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Workshop
Description: The intervention consists of providing educational content for all ICU care providers concerning building staff knowledge surrounding methods to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures). The first intervention is an educational workshop to increase staffs' awareness of the current Choosing Wisely Canada Critical Care strategies and recommendations to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimizing Staff Scheduling
Description: This initiative will focus solely on the nurse subgroup and concerns schedule optimization to ensure the presence of the appropriate number of nurses per shift, thereby reducing stress, burnout and limiting the need for overtime.
Study: NCT06084949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nordic walking or inspiratory muscle training
Description: Nordic walking is a form of low-impact aerobic exercise that incorporates the use of walking poles. And inspiratory muscle training is a type of exercise that provides resistance during the inhalation phase.
Study: NCT05830305

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile health intervention
Description: A protocol-based intervention via phone calls, which includes anti-hypertensive drug adjustment and reinforcement of lifestyle modification, will be implemented.
Study: NCT05128955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splenic artery embolization with vascular embolic coils or plugs
Description: Splenic artery embolization with vascular embolic coils or plugs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splenic artery embolization with vascular embolic coils or plugs
Description: Splenic artery embolization with vascular embolic coils or plugs
Study: NCT04336735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunization app
Description: A transplant specific immunization app will be trialed that 1) provides vaccine information and education, 2) stores vaccine records and 3) provides reminders when vaccines are due
Study: NCT06182566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Convergent ablation
Description: Staged hybrid ablation with CONVERGENT epicardial ablation with ablation of the ligament of Marshall and left atrial appendage clip, followed in second stage by endocardial catheter ablation including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Pulmonary vein isolation using commercially available catheters; including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
Study: NCT05367063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin 100mg or Sitagliptin 100mg
Description: 70 eligible type 2 diabetes patients at high risks of cardiovascular diseases will be randomly assigned by a 1:1 ratio to either Canagliflozin 100 mg once daily or Sitagliptin 100 mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Canagliflozin 100mg or Sitagliptin 100mg
Description: 70 eligible type 2 diabetes patients at high risks of cardiovascular diseases will be randomly assigned by a 1:1 ratio to either Canagliflozin 100 mg once daily or Sitagliptin 100 mg once daily.
Study: NCT06443619

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral USG-deep SAPB with glucose
Description: patients will receive unilateral USG-deep SAPB ; 15 ml 0.5 % isobaric bupivacaine with addition of 15ml glucose 10% to (30 ml total volume).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral USG-deep SAPB without glucose
Description: will receive unilateral USG-deep SAPB; 15ml 0.5% isobaric bupivacaine to be diluted with 15ml isotonic saline0.9% (30 ml total volume).